Not available
Quote | Agenus Inc. (NASDAQ:AGEN)
Last: | $15.13 |
---|---|
Change Percent: | -0.14% |
Open: | $14.55 |
Close: | $15.13 |
High: | $15.15 |
Low: | $14.1102 |
Volume: | 317,114 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Agenus Inc. (NASDAQ:AGEN)
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
Message Board Posts | Agenus Inc. (NASDAQ:AGEN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $AGEN News Article - Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI | whytestocks | investorshangout | 05/03/2023 6:35:51 PM |
shalbyj: TheStreetReports: AI Biotech Stocks to Watch 2023: $IPA, $ONTX, $AGEN, $PBIO https://www.ma | shalbyj | investorshangout | 04/25/2023 1:37:15 PM |
whytestocks: $AGEN News Article - Agenus Receives Fast Track Designation for Botensilimab and Balsti | whytestocks | investorshangout | 04/17/2023 12:00:59 PM |
whytestocks: $AGEN News Article - Agenus' Botensilimab in Combination with Balstilimab Shows 33% Dur | whytestocks | investorshangout | 03/27/2023 3:10:50 PM |
whytestocks: $AGEN News Article - Best Penny Stocks To Buy Now: 3 To Watch Before Next Week | whytestocks | investorshangout | 03/15/2023 8:20:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...